ライフサイエンスコーパス: eosinophil count

1 er measurements (Fe(NO) and peripheral blood eosinophil count).

2 osinophil-derived neurotoxin levels or blood eosinophil counts).

3 to an increased body mass index or a reduced eosinophil count.

4 revalence, total immunoglobulin E (IgE), and eosinophil count.

5 ations was independent of the baseline blood eosinophil count.

6 ting beta2 agonist, irrespective of baseline eosinophil count.

7 and 1 year after (outcome) their most recent eosinophil count.

8 th vilanterol alone were not associated with eosinophil count.

9 limited to histologic EG based on the tissue eosinophil count.

10 s, as reported by CD41, predicted esophageal eosinophil count.

11 pecified subgroup analysis by baseline blood eosinophil count.

12 f controller asthma medication, and absolute eosinophil count.

13 creased and PCO(2) increased with increasing eosinophil count.

14 cantly predicted the presence of high sputum eosinophil counts.

15 eived placebo, independent of baseline blood eosinophil counts.

16 uid neutrophil and lymphocyte counts but not eosinophil counts.

17 1237 with high (>/=200 cells per muL) blood eosinophil counts.

18 mately 0, including correlations with sputum eosinophil counts.

19 between ETP and vWF with neutrophil but not eosinophil counts.

20 vere, uncontrolled asthma and elevated blood eosinophil counts.

21 -course-persistent asthma had elevated blood eosinophil counts.

22 ced clinicopathologic remission with reduced eosinophil counts.

23 rated the ability to reduce blood and tissue eosinophil counts.

24 re not associated with changes in esophageal eosinophil counts.

25 zation significantly enhanced BAL and tissue eosinophil counts.

26 ma Control Questionnaire 5 scores, and blood eosinophil counts.

27 re is no evidence that it reduces esophageal eosinophil counts.

28 tional polynomials to model continuous blood eosinophil counts.

29 ional exhaled nitric oxide values and sputum eosinophil counts.

30 counts, and so were stratified by mean blood eosinophil count: 1262 patients with low (<200 cells per

31 ively, active vs placebo) and gastric mucosa eosinophils counts (239 eosinophils/mm(2) [59-645] vs 25

32 decrease in FEV(1) and an increase in sputum eosinophil counts 24 hours later (after diluent: median,

33 ents were stratified (2:1) by baseline blood eosinophil counts 300 cells per muL or greater and less

34 f 75.1%, median values of 300/mm(3) of blood eosinophil count, 323 kU/L of serum total IgE, and 24 pp

35 0) than subjects with singly increased blood eosinophil counts (40.5% vs 21.1%, P = .01).

36 -threatening exacerbations with median blood eosinophil count (5-95th percentiles) of 0.270 x 10(9) /

37 nts or singly increased Feno levels or blood eosinophil counts (85.7% vs 35.8% or 63.3% or 60%, P < .

38 ed nitric oxide values (14.5 ppb), and blood eosinophil counts (96 cells/muL) than all other groups.

39 imary endpoint was the reduction in absolute eosinophil count (AEC) during the first week of DEC trea

40 RNA expression, was correlated with absolute eosinophil count (AEC).

41 for the evaluation of eosinophilia (absolute eosinophil count [AEC] > 1500/muL) met the criteria for

42 Seropositive patients had higher absolute eosinophil counts (AECs) than seronegative patients (P =

43 The striking elevation in eosinophil counts among the TR group was accompanied by

44 a close relationship between baseline blood eosinophil count and clinical efficacy of mepolizumab in

45 ures of EoE (peak esophageal intraepithelial eosinophil count and EoE histologic scores), endoscopica

46 d persistent asthma irrespective of baseline eosinophil count and had a favourable safety profile, an

47 We investigated the relation between blood eosinophil count and prospective annual asthma outcomes

48 most well established of these are the blood eosinophil count and serum periostin, both of which have

49 IMPACT trial shows that assessment of blood eosinophil count and smoking status has the potential to

50 Peak eosinophil count and surface expression of eosinophil ac

51 ifferentials, explaining 71% of variation in eosinophil counts and 64% of variation in neutrophil cou

52 count-response relation exists between blood eosinophil counts and asthma-related outcomes.

53 sociation between sputum or peripheral blood eosinophil counts and body mass index.

54 ficantly improved intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-re

55 sess the relationship between baseline blood eosinophil counts and efficacy of mepolizumab we did a s

56 osinophilic inflammation [primary endpoints: eosinophil counts and eosinophil cationic protein (ECP)]

57 Clinical studies reveal changes in blood eosinophil counts and eosinophil cationic proteins that

58 Significant reductions in esophageal eosinophil counts and histologic and endoscopic features

59 roduced a significant decrease in esophageal eosinophil counts and improved dysphagia and endoscopic

60 eactions correlated with reductions in blood eosinophil counts and lung function and increases in nas

61 rleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatment of

62 r of controller medications, and total blood eosinophil counts and negatively with the Asthma Control

63 T-cell counts and positively correlated with eosinophil counts and not associated with CD4 T-cell cou

64 nd rs2416257 (A allele associated with lower eosinophil counts and protective against asthma) were co

65 ion of IL33 (A allele associated with higher eosinophil counts and risk for asthma) was correlated wi

66 Blood eosinophil counts and smoking status could be important

67 ts with both increased Feno levels and blood eosinophil counts and subjects with normal Feno levels a

68 ic protein in nasal washes, along with blood eosinophil counts and total and allergen-specific IgE in

69 zed for hemoglobin, white blood cell counts, eosinophil counts and total serum IgE levels, questionna

70 and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in durat

71 score and >75% reduction in gastrointestinal eosinophil count) and the change in total symptom score.

72 Low albumin level, low eosinophil count, and CDI treatment preenrollment were r

73 ance, esophageal gene expression, esophageal eosinophil count, and the relationship between clinical

74 ction of exhaled nitric oxide [Feno], sputum eosinophil count, and urinary bromotyrosine [BrTyr] leve

75 t pulmonary function tests, blood and sputum eosinophil counts, and 1.5-T DCE MR imaging within 7 day

76 production by IL-13-stimulated BECs, sputum eosinophil counts, and asthma severity.

77 evere airflow limitation, had elevated blood eosinophil counts, and at least two exacerbations or one

78 ction correlated with PC20 for methacholine, eosinophil counts, and FEV1.

79 ne the predictive value of IgE levels, blood eosinophil counts, and fraction of exhaled nitric oxide

80 d reduced OVA-induced increases in total and eosinophil counts, and IL-4, IL-5, IL-13, IL-1beta, IL-3

81 ling (in 82% of subjects), markedly elevated eosinophil counts, and increased filaria-specific immuno

82 C20, fraction of exhaled nitric oxide, blood eosinophil counts, and inhaled steroid treatment did not

83 s had higher than normal Feno values, sputum eosinophil counts, and urinary BrTyr levels during the s

84 s (phase 2) during which Feno values, sputum eosinophil counts, and urinary BrTyr levels were measure

85 High pulmonary eosinophil counts are associated with asthma symptoms an

86 Using 2% baseline eosinophil count as a threshold, patients with COPD with

87 vely with nine ascending categories of blood eosinophil count as compared with a reference category o

88 screening periostin concentration, and blood eosinophil counts as covariates.

89 rushings transcriptional signal versus blood eosinophil counts as well as differential expression usi

90 After correction for eosinophil counts, aspirin-induced changes in blood gran

91 values of NSBH, and FeNO, as well as sputum eosinophil counts assessed at baseline of the SIC were d

92 ts, 243 patients (99.1%) had a normal or low eosinophil count at admission.

93 FVC ratio, airways responsiveness, and serum eosinophil count at baseline yielded greater than 80% pr

94 a reduction of at least 50% in the absolute eosinophil count at week 12.

95 ere observed in patients regardless of blood eosinophil counts at enrollment.

96 n the benralizumab 30 mg Q8W group had blood eosinophil counts at least 300 cells per muL and were in

97 Blood eosinophil counts at screening were related to the exace

98 s was found among patients with higher blood eosinophil counts at screening.

99 rate for a greater than 75% decrease in peak eosinophil counts at week 12.

100 FeNO, airway responsiveness, blood eosinophil count (B-Eos) and IgE sensitization to food a

101 ion of exhaled nitric oxide (Feno) and blood eosinophil count (B-Eos) values, markers of local and sy

102 al, an effect not seen in most patients with eosinophil counts below these thresholds.

103 ing placebo was given according to the blood eosinophil count biomarker.

104 tment reduces STH prevalence, total IgE, and eosinophil count but has no effect on IR at the communit

105 reduced the peak esophageal intraepithelial eosinophil count by a mean 86.8 eosinophils per high-pow

106 determine the relationship between the blood eosinophil count, clinical characteristics and gene expr

107 Elevated blood eosinophil counts combined with clinical characteristics

108 mptoms of eosinophilic esophagitis or tissue eosinophil counts compared with placebo.

109 ntly increased BAL fluid and biopsy specimen eosinophil counts compared with those found in control s

110 erbations increased in proportion with blood eosinophil count, compared with a non-ICS dual long-acti

111 s, and FEV1 percent predicted, but not blood eosinophil counts, correctly predicted 69% of sputum eos

112 reatening asthma, we found that a spot blood eosinophil count correlates with severity of respiratory

113 Blood eosinophil count could potentially be used to stratify p

114 Blood eosinophil counts could add predictive value to Global I

115 etermine whether an algorithm based on blood eosinophil counts could safely reduce systemic corticost

116 ials (conducted between 1998 and 2011), with eosinophil count data available for 10 861 patients with

117 ase from baseline of 61.9% in airway mucosal eosinophil counts (day 28; placebo: +19.6%; P = .28), as

118 200 mg) median reduction of 95.8% in airway eosinophil counts (day 84; placebo, 46.7%; P = .06), as

119 y end point was not met, the mean esophageal eosinophil count decreased by 60% with QAX576 versus an

120 creased in 82% of asthmatic patients, sputum eosinophil counts decreased in 60%, and urinary BrTyr le

121 nally, total serum IgE levels and peripheral eosinophil counts decreased.

122 moderate-to-severe asthma and raised sputum eosinophil counts despite inhaled corticosteroid treatme

123 with recurrent exacerbations and high blood eosinophil counts despite use of inhaled corticosteroids

124 Tissue eosinophil counts did not correlate with CCL26 staining.

125 egulatory response, the maintenance of lower eosinophil counts during grass pollen seasons, and sIgE

126 e correlated with improvements in histology, eosinophil counts, endoscopic findings, and symptoms.

127 haled breath (FENO ), spirometry (FEV1 ) and eosinophil count (EOS) in 36 patients with allergic, ste

128 ere evaluated with respect to baseline blood eosinophil counts (eosinophils <300/muL [low] vs >/=300/

129 Intraepithelial peak eosinophil and blood eosinophil counts, esophageal-related symptoms, serum to

130 inophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and pred

131 We sought to determine whether blood eosinophil counts, Feno levels, and IgE levels accuratel

132 on with sputum eosinophil percentages, blood eosinophil counts, Feno levels, and total IgE levels did

133 tionship between observed efficacy and blood eosinophil count for moderate or severe exacerbations, T

134 Baseline eosinophil counts for the NEB and OVB groups were 101 an

135 eas ethnicity, sex, atopy, IgE level, sputum eosinophil count, fraction of exhaled nitric oxide, asth

136 The combination of blood eosinophil count, fractional exhaled nitric oxide, Asthm

137 end point was the change in gastrointestinal eosinophil count from baseline to 2 weeks after the fina

138 revious 12 months, and had a screening blood eosinophil count greater than or equal to 1000 cells/muL

139 Patients with asthma and blood eosinophil counts greater than 400 cells per muL experie

140 , 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per muL.

141 Using either a PC20 </=16 mg/mL or a sputum eosinophil count >/=1% increased the sensitivity to 94%.

142 A FeNO level >/=25 ppb and a sputum eosinophil count >/=2% provided lower sensitivity rates

143 NSBH despite a positive SIC showed a sputum eosinophil count >/=2%, a FeNO level >/=25 ppb, or both

144 2.832, 95%-CI 1.508-5.321, P = 0.001), peak eosinophil count >10 eosinophils/HPF (OR 0.724, 95%-CI 0

145 At baseline, patients with blood eosinophil counts >=150 cells/uL (or >=300 cells/uL in t

146 phenotype were stratified according to blood eosinophil count (>/=150 per cubic millimeter at screeni

147 rate-to-severe asthma and an elevated sputum eosinophil count (>/=2%).

148 ) ratio versus placebo, analysed by baseline eosinophil counts (>/=0, >/=150, >/=300, or >/=450 cells

149 creased Feno levels (>/=20-25 ppb) and blood eosinophil counts (>/=0.3 x 10(9)/L) had a higher preval

150 erbations in patients stratified by baseline eosinophil counts (>/=150 cells per muL, >/=300 cells pe

151 itric oxide values in relationship to sputum eosinophil counts (>2%), as well as to determine whether

152 with mild-to-moderate asthma with high blood eosinophil counts (>=300 cells/muL).

153 , 40 (3.8%) patients with less than 2% blood eosinophil counts had a pneumonia event versus 48 (2.4%)

154 reshold, patients with COPD with lower blood eosinophil counts had more pneumonia events than did tho

155 Profile A infants had higher eosinophil counts, higher cathelicidin levels, and incre

156 ificance of the "treatable trait" high blood eosinophil count in COPD is the same as for asthma remai

157 led corticosteroids (ICS) and baseline blood eosinophil count in patients with chronic obstructive pu

158 rimary outcome was change in mean esophageal eosinophil count in the 5 high-power fields (hpfs) with

159 ated with asthma and six are associated with eosinophil count in the general population.

160 tiple-dose subcutaneous benralizumab reduced eosinophil counts in airway mucosa/submucosa and sputum

161 with eosinophilic asthma and its effects on eosinophil counts in airway mucosal/submucosal biopsy sp

162 een genes and pathways associated with blood eosinophil counts in asthma versus COPD.

163 lter symptoms of eosinophilic esophagitis or eosinophil counts in biopsy samples compared with placeb

164 y mucosa/submucosa and sputum and suppressed eosinophil counts in bone marrow and peripheral blood.

165 Here we report an increase of blood or heart eosinophil counts in humans and mice after myocardial in

166 inary eicosanoid metabolite levels and blood eosinophil counts in patients with AERD who tolerate and

167 vents eosinophilic degranulation and reduces eosinophil counts in primary biliary cirrhosis.

168 investigate increased Feno levels and blood eosinophil counts in relation to lung function, bronchia

169 ) and is correlated with high IgE levels and eosinophil counts in subjects bearing the risk genotype.

170 The mean peak eosinophil counts in the proximal esophagus were 34 eos/

171 sthma symptoms worsened and peripheral blood eosinophil count increased to 813/muL.

172 ion did not improve and her peripheral blood eosinophil count increased.

173 Blood eosinophil count is a promising biomarker of response to

174 We investigated whether blood eosinophil count is a useful biomarker of the long-term

175 treatment for COPD have shown that the blood eosinophil count is associated with the risk of COPD exa

176 ng with aeroallergen sensitization and blood eosinophil counts is useful for guiding treatment select

177 with mepolizumab versus placebo in the blood eosinophil count less than 150 cells/muL subgroup (72% v

178 erol was 0.88 (95% CI 0.74 to 1.04) at blood eosinophil count less than 90 cells per muL and 0.56 (0.

179 l due to clinical relevance]), rectal biopsy eosinophil count less than or equal to 32 cells per high

180 e that patients with COPD and baseline blood eosinophil counts less than 2% have a poorer response to

181 At blood eosinophil counts less than 90 cells per muL and at coun

182 0% (0.79 vs 0.89; p=0.2827) in patients with eosinophil counts lower than 2%.

183 and allergic mediators, lower mast cells and eosinophil counts, lower protein expressions of Th2 cyto

184 The primary outcome was an eosinophil count <1.5 x 109/L at one month and improveme

185 the end of the double-blind phase and a peak eosinophil count <5 eosinophils/high power field.

186 >/=3%, and <5% and >/=5%) and absolute blood eosinophil count (<150 cells/mul, 150 to <300 cells/mul,

187 eumonia events, stratified by baseline blood eosinophil count (<2% vs >/=2% of blood leucocytes) and

188 itric oxide levels (<24 ppb), and (4) sputum eosinophil counts (<2.5%).

189 mly allocated them (1:1; stratified by blood eosinophil count [<300 cells per muL vs >/=300 cells per

190 gnificant decrease in bronchoalveolar lavage eosinophil counts, lung interleukin-13 and interleukin-5

191 cidate the relationship between a spot blood eosinophil count-measured at the onset of a life-threate

192 al serum IgE level (median, 733 kU/L), blood eosinophil count (median, 400 cells/mm(3)), and allergen

193 Blood eosinophil count mediated 29% of the life-course-persist

194 % and it was therefore postulated that blood eosinophil count might also have an effect on the risk o

195 Blood eosinophil counts might predict response to inhaled cort

196 h T(H)2 axis decreases, serum IgE levels and eosinophil counts negatively correlated with age in pati

197 s ratio, 32.6; P = 6.9 x 10(-7)), high blood eosinophil counts (odds ratio, 9.1; P = 2.6 x 10(-6)), a

198 analyses, with 2083 patients (66%) having an eosinophil count of 2% or higher at study entry.

199 one acute exacerbation of COPD, and a sputum eosinophil count of 3.0% or more within the previous yea

200 Eosinophil count of 300 cells/muL or more and aeroallerg

201 e hypereosinophilic syndrome and an absolute eosinophil count of at least 1000 cells per cubic millim

202 ic rhinitis aOR = 1.96 [95% CI = 1.58-2.42]; eosinophil count of at least 150 cells per microliter aO

203 Asthma, allergic rhinitis, eosinophil count of at least 150 cells per microliter, a

204 actors, including asthma, allergic rhinitis, eosinophil count of at least 150 cells per microliter, a

205 her prevalence of asthma, allergic rhinitis, eosinophil count of at least 150 cells per microliter, a

206 0.39-0.58) in patients with a baseline blood eosinophil count of at least 150 cells per muL to 70%; 0

207 In METREO, all patients had a blood eosinophil count of at least 150 per cubic millimeter at

208 stent, moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microliter or

209 % CI, 1.02-7.43) for those with a peripheral eosinophil count of greater than 436 cells/muL.

210 ts and among subgroups with a baseline blood eosinophil count of less than 150 cells/muL, baseline OG

211 ol alone, were 24% in patients with baseline eosinophil counts of >/=2-<4%, 32% for those with counts

212 with counts of 4-<6%, and 42% for those with eosinophil counts of >/=6%.

213 received benralizumab every 4 weeks who had eosinophil counts of 0 or more cells per muL, AER was 0.

214 patient per year; p<0.0001) in patients with eosinophil counts of 2% or higher, and by 10% (0.79 vs 0

215 Patients with circulating eosinophil counts of 2% or more of blood leucocytes resp

216 than 2% and 6818 patients had baseline blood eosinophil counts of 2% or more.

217 Patients with baseline blood eosinophil counts of 220 cells per muL or greater with:

218 th both aeroallergen sensitization and blood eosinophil counts of 300/muL or greater.

219 ds of asthma control for patients with blood eosinophil counts of 400 cells per muL or less versus gr

220 had eosinophilia, with median peak absolute eosinophil counts of 726/mL (interquartile range, 594-99

221 eat analysis, the subjects had baseline peak eosinophil counts of 73 and 77 eos/hpf in the OVB and MD

222 AER among patients with baseline blood eosinophil counts of at least 0 cells per muL was 1.16 (

223 ients were stratified 2:1 according to blood eosinophil counts of at least 300 cells per muL and less

224 om score at week 48, for patients with blood eosinophil counts of at least 300 cells per muL.

225 (FEV1 in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per muL as

226 4043 patients had baseline blood eosinophil counts of less than 2% and 6818 patients had

227 exhaled nitric oxide (Feno) levels and blood eosinophil counts offer additive information in relation

228 ed the trends and correlations between blood eosinophil count on admission with arterial blood gas va

229 The median eosinophil count on day 1 was 0.0 (interquartile range,

230 icant attenuation of allergen-induced sputum eosinophil count on Day 4 following GSK2190915: mean tre

231 Peripheral eosinophil counts on days 1 and 3 of admission and at th

232 and EOs and did not correlate with absolute eosinophil count or disease activity.

233 No differences were documented in blood eosinophil counts or serum markers after eHF intake.

234 sera from most donors unrelated to absolute eosinophil counts or Siglec-8 surface expression.

235 BHR than having normal Feno levels and blood eosinophil counts or singly increased Feno levels or blo

236 ients with increased serum IgE levels, blood eosinophil counts, or both were also negative.

237 the ICS-continuation group in patients with eosinophil counts (out of total white blood cell count)

238 levels significantly correlated with sputum eosinophil counts (P < .0001), suggesting that CCL26 par

239 d subjects with normal Feno levels and blood eosinophil counts (P = .02) after adjusting for confound

240 .001) and the highest quartile of peripheral eosinophil counts (P = .03) but not wheezing symptoms, b

241 scores correlated with increased airway wall eosinophil counts (P = 0.003), blood eosinophil percenta

242 Increased peripheral blood eosinophil counts (patients with EG: 1.09 +/- 0.88 x 10(

243 ncreased and plasma tryptase correlated with eosinophil counts (Pearson r = 0.514; P < 0.01) on aspir

244 027) positively correlated with peak gastric eosinophil counts (Pearson r(2) = .8102, P < .0001).

245 At week 16, mean changes in esophageal eosinophil count per hpf were a reduction of 94.8 +/- 67

246 Primary outcomes were post-treatment maximum eosinophil counts per high-power field (eos/hpf) and a v

247 ates increased progressively with increasing eosinophil count percentage category.

248 Elevated sputum eosinophil counts predict asthma exacerbations and respo

249 sk allele at the IL6 lead variant and higher eosinophil count, pulse pressure, systolic blood pressur

250 (P < .005) and was inversely correlated with eosinophil count (R = -0.67; P = .001).

251 sion was negatively correlated with absolute eosinophil counts (r = -0.46, P < .001), and soluble pla

252 ation found was between IgE levels and blood eosinophil counts (r = 0.33, P < .001); furthermore, all

253 a levels correlated positively with absolute eosinophil counts (r = 0.69, P < .001), suggesting modul

254 inical development program showed that blood eosinophil counts, rather than sputum or tissue eosinoph

255 weak but significant association with sputum eosinophil counts (receiver operating characteristic are

256 d reduced bronchoalveolar lavage (BAL) fluid eosinophil counts, reduced airway resistance in response

257 Having increased Feno levels and blood eosinophil counts related to a higher prevalence of mode

258 (worsening of HES-related symptoms or blood eosinophil count requiring therapeutic escalation) in th

259 risons of symptoms, lung function, and blood eosinophil counts revealed differences that were more pr

260 ho = 0.48), C-reactive-protein (rho = 0.43), eosinophil counts (rho = -0.45), and serum albumin (rho

261 EC) in the first 24 hours posttreatment, the eosinophil count rose significantly in both groups, peak

262 Blood eosinophil counts showed a positive relationship with pe

263 Blood eosinophil counts showed a weak but significant associat

264 antly greater than AUCs for peripheral blood eosinophil counts, sputum neutrophil counts, and combine

265 ry end points included changes in esophageal eosinophil counts, symptoms assessed by questionnaire sc

266 being more corticosteroid responsive at any eosinophil count than current smokers.

267 benralizumab for 12 weeks had lower absolute eosinophil counts than those who received placebo.

268 tly higher total IgE levels and higher blood eosinophil counts than those with the lower-risk genotyp

269 neutrophilia, and despite the wide range in eosinophil counts, the T(H)2 mediators that are thought

270 ma symptoms and reduced the peripheral blood eosinophil count to 0/muL.

271 gies may be effective in reducing esophageal eosinophil counts to <15 per high-power field over a sho

272 orticosteroids effectively reduce esophageal eosinophil counts to <15 per high-power field over a sho

273 Variables, such as blood eosinophil counts, total IgE levels, fraction of exhaled

274 For 2665 patients with elevated blood eosinophil counts, treatment effect with benralizumab ev

275 lesions, treatment of rash, peripheral blood eosinophil count, tumor response, and skin histologic ch

276 f IL-6 (non-Type 2 asthma) and FeNO or blood eosinophil count (Type 2 asthma) identified asthma endot

277 e mean percentage change in gastrointestinal eosinophil count was -86% in the combined AK002 group, a

278 The mean blood eosinophil count was 200/muL (SD, 144/muL).

279 The peak gastric antrum eosinophil count was 283 +/- 164 eosinophils/x400 high-p

280 um of up to 4 days) on days when their blood eosinophil count was at least 0.3 x 10(9) cells per L.

281 On days when the eosinophil count was lower, prednisolone was not adminis

282 riod, a treatment based on the last measured eosinophil count was prescribed for the remaining days w

283 Post-treatment eosinophil counts were 15 and 21 in the OVB and MDI grou

284 DSQ scores were 29.3 and 29.0, and mean peak eosinophil counts were 156 and 130 per hpf in the BOS an

285 DSQ scores were 15.0 and 21.5, and mean peak eosinophil counts were 39 and 113 per high-power field,

286 ine to the end of therapy in peak esophageal eosinophil counts were 59%, 67%, 64%, and 24% in the 1,

287 Feno levels and sputum eosinophil counts were assessed at baseline and 24 hours

288 ionships with pulmonary function testing and eosinophil counts were assessed by using Pearson correla

289 LRTSs and blood eosinophil counts were augmented and lung function was r

290 Measurements of Feno levels and blood eosinophil counts were available in 406 subjects (208 wo

291 score was reduced by 0.47 points, and blood eosinophil counts were reduced by 78%, with similar impr

292 f gastric biopsy specimens, as well as blood eosinophil counts, were analyzed in patients with EG and

293 An elevated blood eosinophil count when asthma is stable predicts exacerba

294 t positive association with the linear blood eosinophil count, whereas in U-BIOPRED, 1197 genes showe

295 hilic inflammation, some have an increase in eosinophil counts, which might be orchestrated by TH2 ce

296 b in patients with asthma and elevated blood eosinophil counts who are inadequately controlled on inh

297 he T2 phenotype was defined by using a blood eosinophil count with a threshold of 300 cells/muL.

298 protocol presented a significant increase in eosinophil counts with increased extracellular DNA in br

299 mined, patients with elevated baseline blood eosinophil counts, with three or more exacerbations in t

300 whether patients with COPD with higher blood eosinophil counts would be more likely to have exacerbat